Clinical Trial

Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric and adult participants who have cholestatic liver disease with pruritus that has been refractory to other therapies, and who have no other treatment options.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-03-31
notable Trial sites reduced: 35 -> 24 locations 2026-03-31
Trial Details
NCT Number NCT06553768
Lead Sponsor Mirum Pharmaceuticals, Inc.
Conditions Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Enrollment 90 participants
Start Date 2024-10-14
Primary Completion 2026-10 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-11